Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix and Twinrix Co-administration in Adolescent Females
NCT00578227Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2007
- Primary completion
- Dec 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (3 arms), sponsored by GSK. Primary endpoints: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies at Month 7, Anti-Heptatis A (HAV) Antibody Titers at Month 7 and 3 more. Started Dec 2007; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00578227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578227.